Rahway, NJ, United States of America

Michel Gallant

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michel Gallant. Retrieved from https://idiyas.com/inventor/michel-gallant-7950odms

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:

goldMedal1 out of 834,513 
Other
 patents

Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Inventor Michel Gallant

Introduction

Michel Gallant, an accomplished inventor based in Rahway, NJ, has made significant contributions to the field of pharmaceuticals. His innovative approach has led to the development of a unique method related to prostaglandin E inhibitors, showcasing his commitment to advancing medical treatments.

Latest Patents

Gallant holds a patent titled "Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore." This patent represents an important advancement in the development of therapeutic solutions aimed at enhancing patient outcomes.

Career Highlights

Throughout his career, Michel Gallant has remained dedicated to research and innovation. His work not only demonstrates his expertise in medicinal chemistry but also reflects his drive to improve health and wellness through scientific discovery.

Collaborations

Gallant's innovative journey is further enriched by his collaborations with esteemed colleagues, including Nicolas Lachance and Marc Labelle. Their combined efforts exemplify the power of teamwork in the realm of scientific research and development.

Conclusion

In conclusion, Michel Gallant's contributions to innovation in the pharmaceutical field are noteworthy. His patent and collaborative spirit continue to inspire future advancements, ensuring a lasting impact on medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…